We highly recommend enabling Javascript while using the BlackBoxRX site.


Risk of Drug Resistance with Use of Cabotegravir for HIV-1 Pre-Exposure Prophylaxis (PrEP) in Undiagnosed HIV-1 Infection

  • Individuals must be tested for HIV-1 infection prior to initiating APRETUDE or oral cabotegravir, and with each subsequent injection of APRETUDE, using a test approved or cleared by the FDA for the diagnosis of acute or primary HIV-1 infection. Drug-resistant HIV-1 variants have been identified with use of APRETUDE by individuals with undiagnosed HIV-1 infection. Do not initiate APRETUDE for HIV-1 PrEP unless negative infection status is confirmed. Individuals who become infected with HIV-1 while receiving APRETUDE for PrEP must transition to a complete HIV-1 treatment regimen.

Patient Counseling Information

Package Inserts

Cabotegravir Kit

Additional Information

Updated January 2022